According to a research report from Morgan Stanley, CSPC PHARMA (01093) saw its third-quarter finished drug sales come in slightly above expectations, with multiple pipeline catalysts ahead that reinforce the bank's investment thesis. The bank maintained its "Overweight" rating on CSPC PHARMA with a target price of HK$12.
Morgan Stanley noted that the company aims to maintain positive growth in finished drug sales through 2027, with no price cut for NBP (National Centralized Procurement), and a roughly 9% price reduction for Mingfule under the national medical insurance catalog, alongside more than 10 innovative drugs in total.
Third-quarter finished drug sales rose 10% year-on-year and 2.5% quarter-on-quarter. Within that, central nervous system (CNS) drugs grew 32% year-on-year, oncology drugs fell 23%, anti-infective drugs rose 2%, cardiovascular drugs fell 15%, respiratory drugs fell 15%, digestive drugs rose 41%, and other drugs fell 2%.
Third-quarter business development revenue reached RMB 373 million, while business development revenue for the first nine months of 2026 totaled RMB 6.3 billion, including partial upfront payments and milestones from the AstraZeneca long-acting peptide platform and the Nectin-4 ADC.
Third-quarter gross margin rose 1 percentage point year-on-year to 67%, the selling and administrative expense ratio for finished drug sales fell 6 percentage points, the R&D ratio remained broadly stable at 31%, and third-quarter adjusted net profit grew 39% year-on-year.
The bank stated that the next catalysts include Phase III readout data for the EGFR ADC in second-line EGFR-mutant non-small cell lung cancer, to be presented at the Asian ESMO in early December, as well as early durability data for PD-1/IL-15 in 2027 and potential globalization updates.
Comments